86 related articles for article (PubMed ID: 3664514)
1. Plasma pharmacokinetics and urinary excretion of hexamethylene bisacetamide metabolites.
Egorin MJ; Zuhowski EG; Cohen AS; Geelhaar LA; Callery PS; Van Echo DA
Cancer Res; 1987 Nov; 47(22):6142-6. PubMed ID: 3664514
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of hexamethylene bisacetamide and its metabolites in leukemic cells.
Egorin MJ; Snyder SW; Cohen AS; Zuhowski EG; Subramanyam B; Callery PS
Cancer Res; 1988 Apr; 48(7):1712-6. PubMed ID: 3162401
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
Egorin MJ; Sigman LM; Van Echo DA; Forrest A; Whitacre MY; Aisner J
Cancer Res; 1987 Jan; 47(2):617-23. PubMed ID: 3791246
[TBL] [Abstract][Full Text] [Related]
4. Induction of differentiation of human promyelocytic leukemia cells (HL60) by metabolites of hexamethylene bisacetamide.
Snyder SW; Egorin MJ; Geelhaar LA; Hamburger AW; Callery PS
Cancer Res; 1988 Jul; 48(13):3613-6. PubMed ID: 3163938
[TBL] [Abstract][Full Text] [Related]
5. Prolonged infusion of hexamethylene bisacetamide: a phase I and pharmacological study.
Rowinsky EK; Ettinger DS; McGuire WP; Noe DA; Grochow LB; Donehower RC
Cancer Res; 1987 Nov; 47(21):5788-95. PubMed ID: 3664482
[TBL] [Abstract][Full Text] [Related]
6. The effect of the monoamine oxidase inhibitor isocarboxazid on the canine metabolism of the cell-differentiating agent hexamethylene bisacetamide.
Conley BA; Sewack GF; Egorin MJ; Subramanyam B; Page JG; Grieshaber CK
Cancer Chemother Pharmacol; 1991; 28(1):33-8. PubMed ID: 2040031
[TBL] [Abstract][Full Text] [Related]
7. Effects of the monoamine oxidase inhibitor, tranylcypromine, on induction of HL60 cell differentiation by hexamethylene bisacetamide and N-acetyl-1,6-diaminohexane.
Snyder SW; Egorin MJ; Zuhowski EG; Schimpff EC; Callery PS
Cancer Commun; 1990; 2(7):231-6. PubMed ID: 2378784
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals.
Young CW; Fanucchi MP; Declan Walsh T; Baltzer L; Yaldaei S; Stevens YW; Gordon C; Tong W; Rifkind RA; Marks PA
Cancer Res; 1988 Dec; 48(24 Pt 1):7304-9. PubMed ID: 3191501
[TBL] [Abstract][Full Text] [Related]
9. Phase I bioavailability and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered via nasogastric tube.
Ward FT; Kelley JA; Roth JS; Lombardo FA; Weiss RB; Leyland-Jones B; Chun HG
Cancer Res; 1991 Apr; 51(7):1803-10. PubMed ID: 2004365
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580).
Conley BA; Forrest A; Egorin MJ; Zuhowski EG; Sinibaldi V; Van Echo DA
Cancer Res; 1989 Jun; 49(12):3436-40. PubMed ID: 2720696
[TBL] [Abstract][Full Text] [Related]
11. An active, aldehydic metabolite of the cell-differentiating agent hexamethylene bisacetamide.
Subramanyam B; Callery PS; Egorin MJ; Snyder SW; Conley BA
Drug Metab Dispos; 1989; 17(4):398-401. PubMed ID: 2571479
[TBL] [Abstract][Full Text] [Related]
12. Involvement of monoamine oxidase and diamine oxidase in the metabolism of the cell differentiating agent hexamethylene bisacetamide (HMBA).
Conley BA; Callery PS; Egorin MJ; Subramanyam B; Geelhaar LA; Pan SS
Life Sci; 1988; 43(9):793-800. PubMed ID: 3137409
[TBL] [Abstract][Full Text] [Related]
13. [Immobilization of N-acetyl-1,6-diaminohexane(NADAH) on diol-silica and study of mechanism of NADAH and hexamethylene bisacetamide(HMBA) inducing tumor cells differentiation].
Xie D; Ren L; Li LS
Se Pu; 1998 Jul; 16(4):327-30. PubMed ID: 11367764
[TBL] [Abstract][Full Text] [Related]
14. Hydrophobic chromatography of the HL-60 cellular fraction co-binding with hexamethylene bisacetamide.
Xie D; Li S; Ren L
J Chromatogr B Biomed Sci Appl; 1997 Jan; 688(2):359-63. PubMed ID: 9061477
[TBL] [Abstract][Full Text] [Related]
15. Approaches to optimal dosing of hexamethylene bisacetamide.
Conley BA; Egorin MJ; Sinibaldi V; Sewack G; Kloc C; Roberts L; Zuhowski EG; Forrest A; Van Echo DA
Cancer Chemother Pharmacol; 1992; 31(1):37-45. PubMed ID: 1333894
[TBL] [Abstract][Full Text] [Related]
16. Identification of metabolites of the cell-differentiating agent hexamethylene bisacetamide in humans.
Callery PS; Egorin MJ; Geelhaar LA; Nayar MS
Cancer Res; 1986 Oct; 46(10):4900-3. PubMed ID: 3756851
[TBL] [Abstract][Full Text] [Related]
17. Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.
Egorin MJ; Van Echo DA; Whitacre MY; Forrest A; Sigman LM; Engisch KL; Aisner J
Cancer Res; 1986 Mar; 46(3):1513-20. PubMed ID: 2935249
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacologic study of hexamethylene bisacetamide in patients with advanced cancer.
Rowinsky EK; Ettinger DS; Grochow LB; Brundrett RB; Cates AE; Donehower RC
J Clin Oncol; 1986 Dec; 4(12):1835-44. PubMed ID: 3783206
[TBL] [Abstract][Full Text] [Related]
19. A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.
Villalona-Calero MA; Petit T; Kuhn J; Cobb P; Kraynak M; Eckhardt SG; Drengler R; Simmons C; Santabarbara P; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1999 Nov; 5(11):3369-78. PubMed ID: 10589747
[TBL] [Abstract][Full Text] [Related]
20. Salivary concentrations of hexamethylene bisacetamide (HMBA) in patients receiving 5-day continuous infusions.
Conley BA; Egorin MJ; Zuhowski EG; Sinibaldi VJ; Peterson DE
Cancer Chemother Pharmacol; 1988; 22(1):65-8. PubMed ID: 3396146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
